Jean Jacques Bienaime Purchases 7,000 Shares of Immunome, Inc. (NASDAQ:IMNM) Stock

Immunome, Inc. (NASDAQ:IMNM) Director Jean Jacques Bienaime purchased 7,000 shares of the firm’s stock in a transaction that occurred on Monday, March 24th. The shares were acquired at an average price of $8.21 per share, for a total transaction of $57,470.00. Following the completion of the transaction, the director now owns 23,615 shares in the company, valued at $193,879.15. The trade was a 42.13 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available at this hyperlink.

Immunome Trading Down 14.7 %

Shares of IMNM stock traded down $1.20 on Tuesday, hitting $6.95. 1,747,431 shares of the stock were exchanged, compared to its average volume of 827,029. The firm has a market capitalization of $604.31 million, a P/E ratio of -0.86 and a beta of 1.93. Immunome, Inc. has a fifty-two week low of $8.12 and a fifty-two week high of $26.70. The business has a 50-day moving average of $9.72 and a 200 day moving average of $11.49.

Immunome (NASDAQ:IMNM) last released its quarterly earnings results on Wednesday, March 19th. The company reported ($0.84) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.68) by ($0.16). Immunome had a negative return on equity of 48.63% and a negative net margin of 3,014.59%. The firm had revenue of $2.74 million for the quarter, compared to analyst estimates of $3.07 million. As a group, research analysts forecast that Immunome, Inc. will post -2.21 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in the business. Charles Schwab Investment Management Inc. boosted its stake in shares of Immunome by 217.0% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 442,477 shares of the company’s stock worth $6,469,000 after buying an additional 302,916 shares during the last quarter. Geode Capital Management LLC grew its stake in Immunome by 13.6% in the third quarter. Geode Capital Management LLC now owns 1,207,455 shares of the company’s stock valued at $17,657,000 after purchasing an additional 144,557 shares in the last quarter. Magnus Financial Group LLC increased its position in shares of Immunome by 107.8% during the 4th quarter. Magnus Financial Group LLC now owns 53,536 shares of the company’s stock worth $569,000 after purchasing an additional 27,777 shares during the last quarter. Point72 Asset Management L.P. raised its stake in shares of Immunome by 22.2% during the 3rd quarter. Point72 Asset Management L.P. now owns 470,647 shares of the company’s stock worth $6,881,000 after purchasing an additional 85,580 shares in the last quarter. Finally, Barclays PLC boosted its holdings in shares of Immunome by 125.9% in the 3rd quarter. Barclays PLC now owns 105,886 shares of the company’s stock valued at $1,547,000 after buying an additional 59,016 shares during the last quarter. Institutional investors own 44.58% of the company’s stock.

Wall Street Analysts Forecast Growth

IMNM has been the topic of several research analyst reports. Guggenheim decreased their target price on Immunome from $35.00 to $25.00 and set a “buy” rating on the stock in a report on Thursday, March 20th. Lifesci Capital initiated coverage on shares of Immunome in a report on Tuesday, March 11th. They set an “outperform” rating and a $20.00 price objective on the stock. Wedbush reaffirmed an “outperform” rating and issued a $33.00 target price on shares of Immunome in a research note on Thursday, March 20th. Finally, Stephens reissued an “overweight” rating and set a $30.00 price target on shares of Immunome in a research note on Thursday, March 20th. Six research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company currently has a consensus rating of “Buy” and an average price target of $25.50.

Immunome Company Profile

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.